Physician profile
Ajay Dar
NPI 1215905286
$3,403.93
in general payments reported to CMS, 2019-2025
37 companies · $343 in 2025
The $343 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $72.95 · 2021: $256 · 2022: $213 · 2023: $853 · 2024: $1,482 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,678.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $539.65 | 2021-2024 | Darzalex, Erleada, Tecvayli |
| Novartis Pharmaceuticals Corporation | $441.40 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $410.60 | 2022-2025 | Calquence, Enhertu, Onglyza |
| Pfizer INC. | $161.63 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $148.30 | 2019-2025 | Keytruda, Lynparza |
| Eisai INC. | $141.59 | 2022-2025 | |
| Intuitive Surgical, INC. | $116.25 | 2023 | |
| Daiichi Sankyo INC. | $113.91 | 2019-2025 | Enhertu, Injectafer |
| Olympus America INC. | $112.77 | 2019 | |
| Astellas Pharma US INC | $98.31 | 2023-2024 | Padcev, Xospata, Xtandi |
| Genentech USA, INC. | $97.86 | 2023-2025 | Venclexta, Gazyva, Lunsumio |
| Tempus Ai, INC | $92.27 | 2024 | |
| Glaxosmithkline, LLC. | $88.98 | 2024 | Zejula, Jemperli, Ojjaara |
| Amgen INC. | $73.88 | 2021-2023 | Lumakras |
| Incyte Corporation | $70.78 | 2021-2024 | Jakafi, Monjuvi |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $69.25 | 2023-2024 | |
| Gilead Sciences, INC. | $63.97 | 2021-2023 | Trodelvy |
| Lilly USA, LLC | $55.87 | 2022-2024 | Retevmo, Jaypirca, Verzenio |
| Takeda Pharmaceuticals U.S.A., INC. | $51.73 | 2024 | Ninlaro, Iclusig |
| Abbvie INC. | $51.68 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $50.74 | 2019-2023 | Imbruvica, Epkinly |
| Tersera Therapeutics LLC | $42.81 | 2023-2025 | Zoladex |
| Myriad Genetic Laboratories, INC. | $33.54 | 2023 | Myrisk |
| Seagen INC. | $32.76 | 2022 | |
| Mirati Therapeutics, INC. | $32.48 | 2023 | Krazati |
| Alexion Pharmaceuticals, INC. | $31.01 | 2024 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $28.15 | 2023 | Opdivo |
| Genmab U.S., INC. | $27.51 | 2024 | Epkinly |
| Blueprint Medicines Corporation | $21.74 | 2023 | Ayvakit |
| Beigene USA, INC. | $21.27 | 2020 | |
| Novocure INC. | $21.18 | 2024 | Optune |
| Kite Pharma, INC. | $16.19 | 2024 | Yescarta |
| Acrotech Biopharma INC. | $15.87 | 2024 | Beleodaq |
| Dilon Technologies, INC. | $15.13 | 2025 | Hemoblast Bellows |
| Rigel Pharmaceuticals, INC. | $12.87 | 2024 | Rezlidhia, Tavalisse |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Dar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.